Novo Nordisk's raised forecast fails to change the debate over its obesity business
CNBC · 38 days ago
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Continue reading at CNBC →Related
Trump's only hope for fighting inflation will make him 'very angry': expert
The Raw Story · 5 hours ago
Stocks stumble on inflation fears, but 2 of our names give us reasons to stay bullish
CNBC · 9 hours ago
Inflation is outpacing wage growth again, squeezing Americans’ paychecks
CNBC · 11 hours ago
Trump's colossal botch has wrenched open an unbelievable opportunity
The Raw Story · 11 hours ago
